Trial Profile
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2020
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Tocotrienols
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CaTo-ROC
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Aug 2019.